Press Releases

  • Afecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators

    IRVINE, CA / August 25, 2026 /PRNewswire/ -- Afecta Pharmaceuticals, focused on developing breakthrough multi-target therapies for complex disorders announced that USPTO has granted the company a new patent entitled "Inhibition of Glial Cell Activation" (US Patent No. 12,673,957).  The patent covers a large library of novel small molecule neuro-immuno modulators.  Activated glial cells cause inflammation […]

  • Afecta Pharmaceuticals Partners with Transcell Biologics to Enhance Afecta’s Drug Development Programs

    IRVINE, CA / January 27, 2025 / Afecta Pharmaceuticals has officially on-boarded Transcell, a next-generation biologics company based in Hyderabad, India, for Digital Animal Replacement Technology (DART) as part of Afecta’s commitment to enhance its drug development programs. The implementation of DART is poised to significantly accelerate Afecta’s clinical development focused on neurodegenerative diseases, ophthalmology […]

  • Afecta Pharmaceuticals Announces Grant of U.S. Patent

    IRVINE, CA / ACCESSWIRE / March 23, 2021 / Afecta Pharmaceuticals, a company focused on developing drugs that modulate key pathways that drive disease processes associated with immune disorders, neurological dysfunction and cancers, announced that the United States Patent and Trademark Office has granted a patent on March 9, 2021 for a class of novel compounds that inhibit the CCL5/RANTES pathway. The patent, U.S. Patent No. 10,940,132, discloses compounds and methods for treating conditions with increased CCL5/RANTES activity. This pathway is a key driver of severe inflammation associated with many diseases.

  • Afecta Pharmaceuticals Enters Into Research Collaboration Agreement With UCI

    Afecta Pharmaceuticals has entered into a research collaboration agreement with the University of California, Irvine (UCI) to interrogate promising drug molecules for the treatment of advanced melanoma using the PharmetRx® AI-based drug discovery and development platform.

  • Afecta Pharmaceuticals CEO to Present at 2019 SF BioHealth Impact Forum

    IRVINE, Calif., January 30, 2019, Afecta Pharmaceuticals, Inc., today announced that its Founder and Chief Executive Officer Bruce Kovacs, MD will present at the BioHealth Impact Forum in San Francisco on Thursday, February 7, 2019. Dr. Kovacs will provide an overview of Afecta's breakthrough product development portfolio for serious skin diseases during the "Groundbreaking Discoveries & Innovations" session.

Next